Shlomzion Aumann

1.1k total citations
25 papers, 160 citations indexed

About

Shlomzion Aumann is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Shlomzion Aumann has authored 25 papers receiving a total of 160 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 10 papers in Genetics and 7 papers in Oncology. Recurrent topics in Shlomzion Aumann's work include Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (6 papers). Shlomzion Aumann is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (6 papers). Shlomzion Aumann collaborates with scholars based in Israel, United States and Italy. Shlomzion Aumann's co-authors include Omar Abdel‐Wahab, Boaz Nachmias, Vladimir Vainstein, Adir Shaulov, Aaron D. Schimmer, Izidore S. Lossos, Isidro Sánchez‐García, Jennifer R. Chapman, Evan R. Roberts and Francisco Vega and has published in prestigious journals such as Blood, Cancer Cell and Biochemical and Biophysical Research Communications.

In The Last Decade

Shlomzion Aumann

20 papers receiving 158 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shlomzion Aumann Israel 7 97 53 51 33 25 25 160
Felix Seyfried Germany 6 74 0.8× 44 0.8× 37 0.7× 38 1.2× 45 1.8× 16 145
Pilar Martínez‐Sánchez Spain 7 50 0.5× 69 1.3× 58 1.1× 24 0.7× 18 0.7× 18 129
Maria Chiara Abbenante Italy 7 80 0.8× 83 1.6× 45 0.9× 45 1.4× 66 2.6× 27 173
Stefan Köhrer Austria 4 69 0.7× 32 0.6× 42 0.8× 41 1.2× 22 0.9× 11 153
Rebecca L. Zon United States 5 150 1.5× 44 0.8× 27 0.5× 26 0.8× 7 0.3× 15 228
Maria López‐Pavía Spain 9 102 1.1× 108 2.0× 21 0.4× 31 0.9× 31 1.2× 21 183
Alexandra Jungová Czechia 6 60 0.6× 95 1.8× 56 1.1× 35 1.1× 16 0.6× 35 130
Salvatore Serravalle Italy 8 120 1.2× 83 1.6× 34 0.7× 9 0.3× 50 2.0× 15 198
Hong L. Tiv United States 5 68 0.7× 50 0.9× 40 0.8× 22 0.7× 8 0.3× 7 130
Mariangela Greco Italy 6 102 1.1× 85 1.6× 17 0.3× 30 0.9× 29 1.2× 14 148

Countries citing papers authored by Shlomzion Aumann

Since Specialization
Citations

This map shows the geographic impact of Shlomzion Aumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shlomzion Aumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shlomzion Aumann more than expected).

Fields of papers citing papers by Shlomzion Aumann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shlomzion Aumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shlomzion Aumann. The network helps show where Shlomzion Aumann may publish in the future.

Co-authorship network of co-authors of Shlomzion Aumann

This figure shows the co-authorship network connecting the top 25 collaborators of Shlomzion Aumann. A scholar is included among the top collaborators of Shlomzion Aumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shlomzion Aumann. Shlomzion Aumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aumann, Shlomzion, et al.. (2025). First case report of talquetamab use in AL amyloidosis. Leukemia & lymphoma. 66(14). 2618–2623.
2.
Gurion, Ronit, Meirav Kedmi, Chava Perry, et al.. (2025). Efficacy and safety of Glofitamab in patients with R/R DLBCL in real life setting– a retrospective study. Annals of Hematology. 104(7). 3821–3827.
3.
Shaulov, Adir, et al.. (2024). Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature. Leukemia & lymphoma. 65(14). 2219–2223. 2 indexed citations
4.
Aumann, Shlomzion, Vladimir Vainstein, Ariela Arad, et al.. (2024). DNMT3A, TET2, and ASXL1 (DTA) Mutations Are Associated with Thrombosis and Bleeding in Patients with Myeloproliferative Neoplasms. Blood. 144(Supplement 1). 3189–3189. 1 indexed citations
5.
Ganzel, Chezi, et al.. (2024). Post‐Relapse Outcomes of Older Patients With NPM1‐Mutated AML Are Favorable With Allo Transplant in Second Remission. European Journal Of Haematology. 114(4). 641–649. 3 indexed citations
6.
Luttwak, Efrat, Esther Drill, Nivetha Ganesan, et al.. (2024). Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma - International, Multi-Center Real-World Experience. Blood. 144(Supplement 1). 1668–1668.
7.
Zuckerman, Tsila, et al.. (2024). For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious. Blood. 144(Supplement 1). 4269–4269. 1 indexed citations
8.
Kastritis, Efstathios, Giovanni Palladini, Paolo Milani, et al.. (2023). Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study. Cancers. 15(6). 1710–1710. 16 indexed citations
9.
Nachmias, Boaz, Svetlana Krichevsky, Moshe E. Gatt, et al.. (2023). Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest. Cancers. 15(22). 5360–5360. 2 indexed citations
10.
Canaani, Jonathan, Daniel A. Pollyea, Marc Schwartz, et al.. (2023). Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. European Journal Of Haematology. 111(3). 365–372. 6 indexed citations
11.
Aumann, Shlomzion, Boaz Nachmias, Dina Ben Yehuda, et al.. (2023). Risk factors and outcomes of COVID‐19 in adult patients with hematological malignancies: A single‐center study showing lower than expected rates of hospitalization and mortality. European Journal Of Haematology. 111(1). 135–145. 1 indexed citations
12.
Shochat, Tzippy, Shlomzion Aumann, Boaz Nachmias, et al.. (2023). Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma—a real-world multicenter retrospective cohort study. Annals of Hematology. 102(8). 2127–2136. 2 indexed citations
13.
Gurion, Ronit, Meirav Kedmi, Chava Perry, et al.. (2023). Efficacy and Safety of Glofitamab in Patients with R/R DLBCL in Real Life Setting - a Retrospective Study. Blood. 142(Supplement 1). 5170–5170. 1 indexed citations
14.
Haran, Michal, et al.. (2023). Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24(3). 187–193.e1.
15.
Aumann, Shlomzion, et al.. (2022). The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 23(18). 10957–10957. 21 indexed citations
16.
Shamriz, Oded, Limor Rubin, Vladimir Vainstein, et al.. (2022). Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma. European Journal Of Haematology. 110(4). 407–413. 3 indexed citations
17.
Nachmias, Boaz, Svetlana Krichevsky, Dvora Filon, et al.. (2022). Monitoring Minimal Residual Disease in <b><i>RUNX1</i></b>-Mutated Acute Myeloid Leukemia. Acta Haematologica. 145(6). 642–649. 4 indexed citations
18.
Shimony, Shai, Jonathan Canaani, Boaz Nachmias, et al.. (2022). Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of Hematology. 101(9). 2001–2010. 10 indexed citations
19.
20.
Parvin, Salma, Ariel Ramírez-Labrada, Shlomzion Aumann, et al.. (2019). LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer Cell. 36(3). 237–249.e6. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felix Seyfried Breakdown of academic impact, for papers by Pilar Martínez‐Sánchez Breakdown of academic impact, for papers by Maria Chiara Abbenante Breakdown of academic impact, for papers by Stefan Köhrer Breakdown of academic impact, for papers by Rebecca L. Zon Breakdown of academic impact, for papers by Maria López‐Pavía Breakdown of academic impact, for papers by Alexandra Jungová Breakdown of academic impact, for papers by Salvatore Serravalle Breakdown of academic impact, for papers by Hong L. Tiv Breakdown of academic impact, for papers by Mariangela Greco
Rankless by CCL
2026